Jornal Vascular Brasileiro
https://www.jvascbras.org/article/doi/10.1590/1677-5449.007817
Jornal Vascular Brasileiro
Review Article

Mecanismos do tromboembolismo venoso no câncer: uma revisão da literatura

Mechanisms of venous thromboembolism in cancer: a literature review

Marcos José Pereira Renni, Mônica Hermida Cerqueira, Ingrid de Araújo Trugilho, Mario Lúcio Cordeiro Araujo Junior, Marcos Arêas Marques, Hilton Augusto Koch

Downloads: 1
Views: 468

Resumo

Existe uma estreita relação entre o tromboembolismo venoso e o câncer. Pacientes com neoplasias apresentam maior incidência de eventos tromboembólicos em sua evolução clínica. A ocorrência desses eventos é considerada um marcador preditivo negativo nesse grupo de pacientes. Revisamos, então, a ativação dos mecanismos de coagulação neste grupo de pacientes. Trata-se de um processo complexo e multifatorial, relacionado tanto a características tumorais, estadiamento clínico, agressividade da doença e sítios tumorais, dentre outros. Novos biomarcadores vêm sendo pesquisados ao longo dos anos na tentativa de correlacioná-los ao risco trombótico, visando uma intervenção que melhore a evolução clínica desses pacientes oncológicos.

Palavras-chave

trombose venosa; câncer; fatores de risco

Abstract

There is a strong relationship between venous thromboembolism and cancer. Patients with tumors have a higher incidence of thromboembolic events in their clinical evolution. The occurrence of such events is considered a negative predictive marker in this group of patients. Thus, we aim to review activation of coagulation mechanisms in this group of patients. Activation of coagulation mechanisms in cancer patients is a complex and multifactorial process, related to tumor characteristics, clinical staging, the disease’s aggressiveness, tumor sites, and additional factors caused by disease progression. New biomarkers have been under investigation over the years in the attempt to correlate them to the risk of thrombosis, aiming to develop interventions that improve the clinical evolution of these cancer patients.

Keywords

venous thrombosis; cancer; risk factors.

References

1. Khorana AA. Risk assessment for cancer-associated thrombosis: what is the best approach? Thromb Res. 2012;129(Suppl 1):10-5. PMid:22682117. http://dx.doi.org/10.1016/S0049-3848(12)70009-9.

2. Lee AYY. Epidemiology and management of venous thromboembolism in patients with cancer. Thromb Res. 2003;110(4):167-72. PMid:14512077. http://dx.doi.org/10.1016/S0049-3848(03)00347-5.

3. Sørensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med. 1998;338(17):1169-73. PMid:9554856. http://dx.doi.org/10.1056/NEJM199804233381701.

4. Furie B, Furie BC. Cancer-associated thrombosis. Blood Cells Mol Dis. 2006;36(2):177-81. PMid:16490369. http://dx.doi.org/10.1016/j.bcmd.2005.12.018.

5. Cogo A, Bernardi E, Prandoni P, et al. Acquired risk factors for deep-vein thrombosis in symptomatic outpatients. Arch Intern Med. 1994;154(2):164-8. PMid:8285811. http://dx.doi.org/10.1001/archinte.1994.00420020066008.

6. Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol. 2005;6(6):401-10. PMid:15925818. http://dx.doi.org/10.1016/S1470-2045(05)70207-2.

7. Blom JW, Vanderschoot JP, Oostindiër MJ, Osanto S, van der Meer FJ, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66.329 cancer patients: results of a record linkage study. J Thromb Haemost. 2006;4(3):529-35. PMid:16460435. http://dx.doi.org/10.1111/j.1538-7836.2006.01804.x.

8. Khorana AA. Cancer and thrombosis: implications of published guidelines for clinical practice. Ann Oncol. 2009;20(10):1619-30. PMid:19561038. http://dx.doi.org/10.1093/annonc/mdp068.

9. Prandoni P, Lensing AW, Büller HR, et al. Deep vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med. 1992;327(16):1128-33. PMid:1528208. http://dx.doi.org/10.1056/NEJM199210153271604.

10. Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol. 2009;27(29):4839-47. PMid:19720906. http://dx.doi.org/10.1200/JCO.2009.22.3271.

11. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, pro thrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6):715-22. PMid:15701913. http://dx.doi.org/10.1001/jama.293.6.715.

12. Sud R, Khorana AA. Cancer-associated thrombosis: risk factors, candidate biomarkers and a risk model. Thromb Res. 2009;123(Suppl 4):18-21. PMid:19303497. http://dx.doi.org/10.1016/S0049-3848(09)70137-9.

13. Shen VS, Pollak EW. Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified? South Med J. 1980;73(7):841-3. PMid:7384840. http://dx.doi.org/10.1097/00007611-198007000-00005.

14. Varki A. Trousseau’s syndrome: multiple definitions and multiple mechanisms. Blood. 2007;110(6):1723-9. PMid:17496204. http://dx.doi.org/10.1182/blood-2006-10-053736.

15. Sood SL. Cancer-associated thrombosis. Curr Opin Hematol. 2009;16(5):378-85. PMid:19606029. http://dx.doi.org/10.1097/MOH.0b013e32832ea31b.

16. Parkin M, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999;49(1):33-64, 1. PMid:10200776. http://dx.doi.org/10.3322/canjclin.49.1.33.

17. Rickles FR, Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res. 2001;102(6):V215-24. PMid:11516455. http://dx.doi.org/10.1016/S0049-3848(01)00285-7.

18. Rickles FR, Patierno S, Fernandez PM. Tissue factor, thrombin, and cancer. Chest. 2003;124(3, Suppl 3):58-68. PMid:12970125. http://dx.doi.org/10.1378/chest.124.3_suppl.58S.

19. Otten HM, Mathijssen J, ten Cate H, et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med. 2004;164(2):190-4. PMid:14744843. http://dx.doi.org/10.1001/archinte.164.2.190.

20. Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med. 2006;119(1):60-8. PMid:16431186. http://dx.doi.org/10.1016/j.amjmed.2005.06.058.

21. Renni MJ, Russomano FB, Mathias LF, Koch HA. Thromboembolic event as a prognostic factor for the survival of patients with stage III B cervical cancer. Int J Gynecol Cancer. 2011;21(4):706-10. PMid:21546873.

22. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3):632-4. PMid:17319909. http://dx.doi.org/10.1111/j.1538-7836.2007.02374.x.

23. Mandalà M, Reni M, Cascinu S, et al. Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. Ann Oncol. 2007;18(10):1660-5. PMid:17660490. http://dx.doi.org/10.1093/annonc/mdm284.

24. Connolly GC, Khorana AA. Emerging risk stratification approaches to cancer associated thrombosis: risk factors, biomarkers and a risk score. Thromb Res. 2010;125(Suppl 2):1-7. PMid:20433985. http://dx.doi.org/10.1016/S0049-3848(10)00227-6.

25. Prandoni P. Venous thromboembolism risk and management in women with cancer and thrombophilia. Gend Med. 2005;2(Suppl A):S28-34. PMid:16551554. http://dx.doi.org/10.1016/S1550-8579(05)80062-2.

26. Shoji M, Hancock WW, Abe K, et al. Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. Am J Pathol. 1998;152(2):399-411. PMid:9466566.

27. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100(10):3484-8. PMid:12393647. http://dx.doi.org/10.1182/blood-2002-01-0108.

28. Tabak D, Torres LG, Nahoum B. Câncer e trombose. Rev Onco& [revista eletrônica]. 2011 [citado 2017 jul 28]; (4):26-32. https://issuu.com/revista-onco/docs/onco_4.

29. Khorana AA, Rao MV. Approaches to risk-stratifying cancer patients for venous thromboembolism. Thromb Res. 2007;120(Suppl 2):S41-50. PMid:18023712. http://dx.doi.org/10.1016/S0049-3848(07)70129-9.

30. Rodriguez AO, Wun T, Chew H, Zhou H, Harvey D, White RH. Venous thromboembolism in ovarian cancer. Gynecol Oncol. 2007;105(3):784-90. PMid:17408726. http://dx.doi.org/10.1016/j.ygyno.2007.02.024.

31. Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy- associated venous thromboembolism in a prospective observational study. Cancer. 2005;104(12):2822-9. PMid:16284987. http://dx.doi.org/10.1002/cncr.21496.

32. Tateo S, Mereu L, Salamano S, et al. Ovarian cancer and venous thromboembolic risk. Gynecol Oncol. 2005;99(1):119-25. PMid:15990161. http://dx.doi.org/10.1016/j.ygyno.2005.05.009.

33. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: risk analysis using Medicare claims data. Medicine. 1999;78(5):285-91. PMid:10499070. http://dx.doi.org/10.1097/00005792-199909000-00001.

34. Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost. 2002;87(4):575-9. PMid:12008937.

35. Zwicker JI, Furie BC, Furie B. Cancer-associated thrombosis. Crit Rev Oncol Hematol. 2007;62(2):126-36. PMid:17293122. http://dx.doi.org/10.1016/j.critrevonc.2007.01.001.

36. Ay C, Pabinger I, Cohen AT. Cancer-associated venous thromboembolism: burden, mechanism, and management. Thromb Haemost. 2017;117(2):219-30. PMid:27882374. http://dx.doi.org/10.1160/TH16-08-0615.

37. Chung I, Lip GY. Virchow’s triad revisited: blood constituents. Pathophysiol Haemost Thromb. 2003;33(5-6):449-54. PMid:15692259. http://dx.doi.org/10.1159/000083844.

38. López JA, Kearon C, Lee AY. Deep venous thrombosis. Hematology (Am Soc Hematol Educ Program). 2004;2004(1):439-56. PMid:15561697. http://dx.doi.org/10.1182/asheducation-2004.1.439.

39. Altman R, Herrera RN. Trombosis: fisiologia, mecanismos de enfermedad y tratamiento. v. 3. Buenos Aires: Edimed; 2008.

40. Rak J, Milsom C, May L, Klement P, Yu J. Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy. Semin Thromb Hemost. 2006;32(1):54-70. PMid:16479463. http://dx.doi.org/10.1055/s-2006-933341.

41. Dvorak HF, Rickles FR. Malignancy and hemostasis. In: Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN, editors. Hemostasis and thrombosis: basic principles and clinical practice. 5th ed. Philadelphia: Lippincott-Raven; 2006. p. 851-73.

42. Falanga A, Rickles FR. The pathogenesis of thrombosis in cancer. N Oncol Thromb. 2005;1:9-16.

43. Tesselaar ME, Romijn FP, Van Der Linden IK, Prins FA, Bertina RM, Osanto S. Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost. 2007;5(3):520-7. PMid:17166244. http://dx.doi.org/10.1111/j.1538-7836.2007.02369.x.

44. Rickles FR. Cancer and thrombosis in women molecular mechanisms. Thromb Res. 2009;123(Suppl 2):S16-20. PMid:19217469. http://dx.doi.org/10.1016/S0049-3848(09)70004-0.

45. Gordon SG, Cross BA. A factor X-activating cysteine protease24. malignant tissue. J Clin Invest. 1981;67(6):1665-71. PMid:7016920. http://dx.doi.org/10.1172/JCI110203.

46. Ay C, Simanek R, Vormittag R, et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood. 2008;112(7):2703-8. PMid:18539899. http://dx.doi.org/10.1182/blood-2008-02-142422.

47. Ay C, Dunkler D, Marosi C, et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116(24):5377-82. PMid:20829374. http://dx.doi.org/10.1182/blood-2010-02-270116.

48. Ay C, Simanek R, Vormittag R, et al. High plasma 4 levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood. 2008;112(7):2703-8. PMid:18539899. http://dx.doi.org/10.1182/blood-2008-02-142422.

5cd2e7cc0e8825fa0e632f90 jvb Articles

J Vasc Bras

Share this page
Page Sections